OPEN END TURBO OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 03:49:37 2024-07-12 pm EDT | ||
| 14.02 EUR | +1.08% |
|
| Current month | -13.64% | ||
| 1 month | -6.79% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 14.02 | +1.08% |
| 24-07-11 | 13.87 | -1.07% |
| 24-07-10 | 14.02 | -2.91% |
| 24-07-09 | 14.44 | -1.77% |
| 24-07-08 | 14.7 | -5.10% |
Delayed Quote Börse Stuttgart
Last update July 12, 2024 at 03:49 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JK1XP6 |
| ISIN | DE000JK1XP65 |
| Date issued | 2024-01-16 |
| Strike | 641 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 19.31 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 23.43 € |
|---|---|
| Lowest since issue | 13.66 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
492.1
USD
Average target price
473.1
USD
Spread / Average Target
-3.87%
- Stock Market
- Certificates
- Certificat
